COMMUNIQUÉS West-GlobeNewswire

Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market
18/05/2026
Ramat Gan, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological [...]
BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting
18/05/2026
FLORHAM PARK, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and other [...]
SEED Therapeutics to Present Phase 1 Trial Design for ST-01156, a First-in-Human Oral RBM39 Molecular Glue Degrader, at 2026 ASCO Annual Meeting
18/05/2026
KING OF PRUSSIA, Pa., May 18, 2026 (GLOBE NEWSWIRE) -- SEED Therapeutics, Inc. (“SEED”), a clinical-stage biotechnology company developing rationally designed molecular glue degraders, today announced that it will [...]
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
18/05/2026
WATERTOWN, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, [...]
Juniper Biosciences Appoints Renowned Radiopharmaceutical Expert Jason S. Lewis, Ph.D. as Chair of Newly Formed Scientific Advisory Board
18/05/2026
BRIDGEWATER, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- Juniper Biosciences, a cutting-edge radiopharmaceutical drug development company, today announced the launch of its Scientific Advisory Board (SAB) and the appointment [...]
GMR Solutions Inc. Announces Ratings Upgrade and Debt Reduction
18/05/2026
Post-IPO rating improvement from S&P Global Ratings and Moody’s Ratings LEWISVILLE, Texas, May 18, 2026 (GLOBE NEWSWIRE) -- GMR Solutions Inc. (NYSE: GMRS) and its wholly owned subsidiary Global Medical Response, [...]
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
18/05/2026
Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable license Phase 1 initiation for CT-202 trial expected in third quarter of 2026 PHILADELPHIA, May 18, 2026 [...]
Vincentage Pharma Reports Positive Top-Line Results from Pivotal Phase 3 Trial of VCT220 in Obese or Overweight Chinese Adults
18/05/2026
CHENGDU, China, May 18, 2026 (GLOBE NEWSWIRE) -- Vincentage Pharma Co., Ltd. (the “Company”) today announced positive top-line results from the Company’s pivotal Phase 3 trial evaluating its internally discovered, [...]
JASCAYD® (nerandomilast) approved in Japan, advancing global access to a new IPF and PPF treatment
18/05/2026
Not intended for UK and US audiences JASCAYD ® (nerandomilast) now approved by Japan’s MHLW for the treatment of adults with idiopathic pulmonary fibrosis and adults with progressive pulmonary fibrosis Approval enables [...]
Philips to deliver vital technology for hospital-at-home care for up to 15,000 patients annually in Region Stockholm
18/05/2026
May 18, 2026 Philips-led consortium selected through Karolinska University Hospital-led Region Stockholm tender to deliver advanced remote monitoring for complex patients Stockholm, Sweden - Royal Philips (NYSE: PHG, [...]
Cytovation to Evaluate Getacatetide (CY-101) in Combination with Checkpoint Inhibitor Tislelizumab in Colorectal Cancer
18/05/2026
Phase 2 study to evaluate combination therapy in patients with metastatic colorectal cancer, targeting β-catenin-driven immune exclusion in liver metastases BeOne Medicines to supply tislelizumab (a PD-1 inhibitor) for [...]
Byondis Establishes Scientific Advisory Board of Recognized Leaders in Oncology Research and ADC Development
18/05/2026
Global experts in antibody-drug conjugate (ADC) development, oncology clinical development and early-phase trial design, appointed to support advancement of Byondis’ differentiated ADC pipeline and a new generation of [...]
NovalGen Appoints Dr Laurent Fischer as Chair of the Board
18/05/2026
LONDON, May 18, 2026 (GLOBE NEWSWIRE) -- NovalGen today announced the appointment of Dr Laurent Fischer, a globally recognized biopharmaceutical executive, as Non-Executive Chair of the Board of Directors with immediate [...]
Ipsen lance un nouveau programme de rachat d’actions
18/05/2026
Ipsen lance un nouveau programme de rachat d’actions PARIS, FRANCE, 18 MAI 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) annonce aujourd'hui avoir confié à un prestataire de services d’investissement un mandat à l’effet de [...]
Ipsen initiates a new share buy-back program
18/05/2026
Ipsen initiates a new share buy-back program PARIS, FRANCE, 18 MAY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it has appointed an investment services provider to purchase an aggregate number of up to [...]
AVITA Medical to Host Investor Webinar Briefing
18/05/2026
VALENCIA, Calif., May 17, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective [...]
Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026
17/05/2026
CARLSBAD, Calif., May 17, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, will announce data [...]
New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer
17/05/2026
More durable, deeper PSA response in patients treated with Pluvicto plus standard of care (ARPI + ADT) vs. SoC alone Deep PSA reduction higher in patients receiving Pluvicto combination vs. SoC at 12, 24 and 48 weeks [...]
Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
17/05/2026
Data presented by Johnson & Johnson at the 2026 European Society for Radiotherapy and Oncology (ESTRO) Annual Meeting PARIS and CAMBRIDGE, Mass., May 17, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ [...]

Pages